Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)

• Status: Unknown status
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.

• Phase: N/A

Details

• Lead Sponsor: Hospital Authority, Hong Kong
• Collaborator: Hong Kong Nasopharyngeal Cancer Study Group Limited
• Treatments: Fluorouracil

Criteria

Inclusion Criteria:

• Undifferentiated or non-keratinizing carcinoma

• Tumor staged as N2-3

• No evidence of distant metastasis M0

• Performance status:0-2

• Marrow: WBC >= 4 and platelet >= 100

• Renal: creatinine clearance >= 60

• Informed consent

Exclusion Criteria:

• WHO type I squamous cell carcinoma or adenocarcinoma

• Age >= 70

• Palliative intent or tumor extent mandating AP opposing facio-cervical fields

• Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years

• Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume

• Previous chemotherapy

• Patient is pregnant or lactating